当前位置: 首页 >> 检索结果
1. 2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial.
作者: Zachary T Yoneda.;Matthew O'Neill.;Diane M Crawford.;Mingfang Ao.;Lili Sun.;Majd A El-Harasis.;Lisa Pitchford.;John A Rathmacher.;Jay Montgomery.;Sharon T Shen.;Juan Carlos Estrada.;Pablo J Saavedra.;Christopher R Ellis.;Travis Richardson.;Arvindh Kangasundram.;George H Crossley.;Wendall S Akers.;Fei Ye.;Dan M Roden.;Gregory F Michaud.;M Benjamin Shoemaker.
来源: Circ Arrhythm Electrophysiol. 2025年18卷8期e013378页
Inflammation is a common mechanism for atrial fibrillation (AF). 2-Hydroxybenzylamine (2-HOBA) is a novel therapeutic that scavenges isolevuglandins-a downstream mediator of inflammation and oxidative stress. 2-HOBA is safe and reduces AF in mice, prompting a first-in-human pilot clinical trial.
2. Impacts of Reducing Sitting Time or Increasing Sit-to-Stand Transitions on Blood Pressure and Glucose Regulation in Postmenopausal Women: Three-Arm Randomized Controlled Trial.
作者: Sheri J Hartman.;Andrea Z LaCroix.;Dorothy D Sears.;Loki Natarajan.;Rong W Zablocki.;Ruohui Chen.;Jeffrey S Patterson.;Lindsay Dillon.;James F Sallis.;Simon Schenk.;David W Dunstan.;Neville Owen.;Dori E Rosenberg.
来源: Circulation. 2025年152卷8期492-504页
Public health and clinical guidelines identify the importance of sedentary behaviors for cardiovascular diseases, particularly among postmenopausal women. The goal of this trial was to compare the behavioral and physiological impacts of 2 distinct approaches to changing sedentary behaviors.
3. Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial.
作者: Chisato Izumi.;Masashi Amano.;Yusuke Yoshikawa.;Satsuki Fukushima.;Hitoshi Yaku.;Kiyoyuki Eishi.;Taichi Sakaguchi.;Nobuhisa Ohno.;Arudo Hiraoka.;Kenji Okada.;Yoshikatsu Saiki.;Takashi Miura.;Tatsuhiko Komiya.;Manabu Minami.;Haruko Yamamoto.;Katsuhiro Omae.; .
来源: Circ Cardiovasc Interv. 2025年18卷7期e015108页
Anticoagulant therapy with vitamin K antagonists is recommended in the current guidelines for 3 to 6 months following bioprosthetic valve replacement. However, in the era of direct oral anticoagulants, there is a paucity of evidence regarding the efficacy and safety of direct oral anticoagulants in this patient group.
4. Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
作者: Samer Al Said.;Siddharth M Patel.;Robert P Giugliano.;David A Morrow.;Erica L Goodrich.;Sabina A Murphy.;Bruce Hug.;Sanobar Parkar.;Shih-Ann Chen.;Shaun G Goodman.;Boyoung Joung.;Robert G Kiss.;Wojciech Wojakowski.;Jeffrey I Weitz.;Dan Bloomfield.;Marc S Sabatine.;Christian T Ruff.
来源: Circulation. 2025年152卷5期290-296页
Combining antiplatelet therapy (APT) with conventional anticoagulants increases the risk of bleeding. In the AZALEA-TIMI 71 trial (Safety and Tolerability of Abelacimab [MAA868] vs Rivaroxaban in Patients With Atrial Fibrillation), the novel factor XI inhibitor abelacimab significantly reduced the risk of bleeding compared with rivaroxaban in patients with atrial fibrillation. Whether the safety of combination antithrombotic therapy differs in the context of factor XI inhibition has not been well characterized.
5. Cost-Effectiveness of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascular Disease.
作者: Louise B Russell.;Kevin G M Volpp.;Mitesh S Patel.;Neel P Chokshi.;Samantha Coratti.;David Farraday.;Laurie Norton.;Charles Rareshide.;Jingsan Zhu.;Tamar Klaiman.;Julia E Szymczak.;Dylan S Small.;Alexander C Fanaroff.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷7期e011839页
The BE ACTIVE trial (Behavioral Economic Approaches to Increase Physical Activity Among Patients with Elevated Risk for Cardiovascular Disease) documented the effectiveness, compared with an attention control arm that received daily text messages, of gamification, financial incentives, or gamification+financial incentives to increase steps/day. Increases in daily step count are associated with longer life expectancy, but understanding the cost-effectiveness of these interventions is essential for payers and other stakeholders seeking to implement findings.
6. Identifying a Heterogeneous Effect of Atrial Fibrillation Screening in Older Adults: A Secondary Analysis of the VITAL-AF Trial.
作者: Sachin J Shah.;Jay M Iyer.;Leila Agha.;Yuchiao Chang.;Jeffrey M Ashburner.;Steven J Atlas.;David D McManus.;Patrick T Ellinor.;Steven A Lubitz.;Daniel E Singer.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷7期e011482页
One-time atrial fibrillation (AF) screening trials in older adults have produced mixed results. In a secondary analysis of the VITAL-AF trial, we aimed to identify a subset of people in whom such screening is effective, using effect-based and risk-based approaches.
7. A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients With Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD Trial.
作者: Kristoffer Grundtvig Skaarup.;Niklas Dyrby Johansen.;Lisbet Brandi.;Morten Kofod Lindhardt.;Jesper N Bech.;My Svensson.;Tilde Kristensen.;Anne Daugaard Thuesen.;Majbritt Grønborg Knudsen.;Jan Dominik Kampmann.;Mads Hornum.;Birgitte Ørts.;Daniel Modin.;Mats C H Lassen.;Kira Hyldekær Janstrup.;Brian L Claggett.;Muthiah Vaduganathan.;Ankeet S Bhatt.;Harriette G C Van Spall.;Jens Ulrik Stæhr Jensen.;Faiez Zannad.;Scott D Solomon.;Anne Møller.;Rikke Borg.;Henrik Birn.;Ditte Hansen.;Tor Biering-Sørensen.
来源: Circulation. 2025年152卷6期369-383页
Many individuals with chronic kidney disease (CKD) face a considerable but modifiable risk of cardiovascular and renal outcomes because of suboptimal implementation of guideline-directed medical therapy (GDMT). We investigated whether electronic letter-based nudges delivered to individuals with CKD and their general practices could increase GDMT uptake.
8. Impact of Initial Extensive Ablation on Left Atrial Gaps During Redo Procedures and Subsequent Outcomes in Persistent Atrial Fibrillation.
作者: Masato Okada.;Koichi Inoue.;Nobuaki Tanaka.;Masaharu Masuda.;Tetsuya Watanabe.;Nobuhiko Makino.;Yasuyuki Egami.;Takafumi Oka.;Hitoshi Minamiguchi.;Miwa Miyoshi.;Takashi Kanda.;Yasuhiro Matsuda.;Masato Kawasaki.;Koji Tanaka.;Yuko Hirao.;Shungo Hikoso.;Akihiro Sunaga.;Tomoharu Dohi.;Daisaku Nakatani.;Katsuki Okada.;Yohei Sotomi.;Yasushi Sakata.; .
来源: Circ Arrhythm Electrophysiol. 2025年18卷6期e013612页
The efficacy of extensive linear ablation strategies, in addition to pulmonary vein (PV) isolation, remains controversial in persistent atrial fibrillation (AF) ablation. Gaps in previously ablated lesions can induce arrhythmias and potentially decrease the effectiveness of extensive ablation. This study evaluated the incidence of conduction gaps, gap-related reentry, and subsequent recurrence following redo AF ablation in the EARNEST-PVI trial (Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation; REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03514693).
9. Randomized Study Comparing Angiography Guidance With Physiology Guidance After PCI: The EASY-PREDICT Study.
作者: Paola Ulacia Flores.;Tomas Cieza.;Safia Ouarrak.;Andrés Ruhl.;Siddharta Mengi.;Robert De Larochellière.;David Garcia-Labbé.;Jean-Pierre Déry.;Anthony Poulin.;Éric Larose.;Bernard Noël.;Can Manh Nguyen.;Jean-Michel Paradis.;Olivier F Bertrand.
来源: Circ Cardiovasc Interv. 2025年18卷7期e015165页
Physiology assessment of coronary lesion prepercutaneous coronary intervention (PCI) using hyperemic and nonhyperemic pressure ratios is useful to determine if a lesion requires treatment. Whether the physiology after PCI is superior to angiography guidance only is unknown. The study sought to investigate whether post-PCI physiology improves clinical outcomes compared with standard angiographic guidance.
10. Marshall-Plan Ablation Strategy Versus Pulmonary Vein Isolation in Persistent AF: A Randomized Controlled Trial.
作者: Nicolas Derval.;Romain Tixier.;Josselin Duchateau.;Xavier Bouteiller.;Timothé Loock.;Arnaud Denis.;Rémi Chauvel.;Benjamin Bouyer.;Marine Arnaud.;Masaaki Yokoyama.;Christopher Kowalewski.;Cinzia Monaco.;Ciro Ascione.;Frédéric Sacher.;Mélèze Hocini.;Pierre Jaïs.;Michel Haïssaguerre.;Thomas Pambrun.
来源: Circ Arrhythm Electrophysiol. 2025年18卷5期e013427页
Beyond pulmonary vein (PV) isolation, the optimal ablation strategy for persistent atrial fibrillation (AF) remains poorly defined. The purpose of this study was to compare 2 ablation strategies in the treatment of patients with persistent AF: a comprehensive ablation strategy based on anatomic considerations versus PV isolation alone.
11. 10-Year Outcomes of Deferred or Conventional Stent Implantation in Patients With STEMI (DANAMI-3-DEFER).
作者: Jasmine Melissa Marquard.;Thomas Engstrøm.;Henning Kelbæk.;Rasmus Paulin Beske.;Utsho Islam.;Dan Eik Høfsten.;Lene Holmvang.;Frants Pedersen.;Christian Juhl Terkelsen.;Evald Høj Christiansen.;Hans-Henrik Tilsted.;Charlotte Glinge.;Reza Jabbari.;Ashkan Eftekhari.;Bent Raungaard.;Peter Clemmensen.;Hans Erik Bøtker.;Lisette Okkels Jensen.;Lars Køber.;Jacob Thomsen Lønborg.
来源: Circ Cardiovasc Interv. 2025年18卷6期e015369页
Primary percutaneous coronary intervention (PCI) with stenting is recommended in ST-segment-elevation myocardial infarction. Immediate stenting may cause distal embolization, microvascular damage, and flow disturbances, leading to adverse outcomes. We report the 10-year clinical outcomes of deferred stenting versus conventional PCI in patients with ST-segment-elevation myocardial infarction.
12. Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial.
作者: David E Kandzari.;Felix Mahfoud.;Raymond R Townsend.;Kazuomi Kario.;Michael A Weber.;Roland E Schmieder.;Konstantinos Tsioufis.;Stuart Pocock.;Minglei Liu.;Vanessa DeBruin.;Sandeep Brar.;Michael Böhm.
来源: Circ Cardiovasc Interv. 2025年18卷7期e015194页
Six-month results from the SPYRAL HTN-ON MED trial (SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral Multi-Electrode Renal Denervation System) demonstrated that renal denervation (RDN) reduced office blood pressure (BP), and not 24-hour ambulatory systolic BP, compared with sham control in hypertensive patients. In this prespecified analysis of the ON MED trial, long-term changes in BP, antihypertensive drug use, and safety outcomes through 24 months are compared between RDN and sham control groups.
13. Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.
作者: Albert Wiegman.;Amy L Peterson.;Robert A Hegele.;Eric Bruckert.;Anja Schweizer.;Anastasia Lesogor.;Yibo Wang.;Joep Defesche.
来源: Circulation. 2025年151卷25期1758-1766页
Homozygous familial hypercholesterolemia (HoFH) is a genetic disease characterized by high levels of low-density lipoprotein cholesterol (LDL-C) present from birth, leading to early-onset and progressive atherosclerotic cardiovascular disease. Early treatment initiation is crucial for cardiovascular risk reduction; however, many patients do not reach LDL-C treatment goals. Inclisiran, a small interfering RNA targeting hepatic PCSK9 (proprotein convertase subtilisin/kexin type 9), is effective and well tolerated in adult patients with hyperlipidemia; however, it has not yet been studied in pediatric patients.
14. Sex-Related Prognosis of VA-ECMO-Treated Cardiogenic Shock: A Post Hoc Analysis of the HYPO-ECMO Trial.
作者: Guillaume Baudry.;Nicolas Girerd.;Kevin Duarte.;Luca Monzo.;Clément Delmas.;Harriette G C Van Spall.;Antoine Kimmoun.;Bruno Levy.
来源: Circ Heart Fail. 2025年18卷8期e012702页
The sex-related prognosis of patients with cardiogenic shock undergoing venoarterial extracorporeal membrane oxygenation remains unclear. Our analyses aim to assess sex-specific outcomes in patients with cardiogenic shock receiving venoarterial extracorporeal membrane oxygenation and explore whether the effect of moderate hypothermia on clinical outcomes was modified by sex.
15. Periaortic Fat Attenuation on Nongated Noncontrast Chest CT Images to Assess Changes in Arterial Inflammation: Impact of Atorvastatin.
作者: Guillaume Goudot.;Shady Abohashem.;Michael T Osborne.;Wesam Aldosoky.;Taha Z Ahmad.;Michael T Lu.;Borek Foldyna.;Ahmed Tawakol.
来源: Circ Cardiovasc Imaging. 2025年18卷7期e017248页
Imaging markers of atherosclerotic inflammation are needed to enhance cardiovascular risk assessment and evaluate the impact of therapies. We sought to test the hypothesis that treatments impacting arterial inflammation can be evaluated using a simplified measure of periaortic fat attenuation (FA) assessed on noncontrast, nongated computed tomography of the descending thoracic aorta.
16. Diastolic Perfusion Pressure Predicts Response to Inotropes and Vasopressors and Benefit From Mechanical Circulatory Support in Cardiogenic Shock.
作者: Hoong Sern Lim.;Dagmar Vondrakova.;Jan Belohlavek.;Richard Rokyta.;Petr Ostadal.
来源: Circ Heart Fail. 2025年18卷7期e012847页
Hemodynamic response to escalation of vasoactive drugs has not been well-characterized in patients with cardiogenic shock (CS). We tested the hypothesis that lower diastolic perfusion pressure (DPP=diastolic blood pressure-right atrial pressure) was associated with more limited hemodynamic response to uptitration of vasoactive drugs and with possible benefit from early mechanical circulatory support in patients with CS.
17. Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial.
作者: Tetsuya Ishikawa.;Masahiro Natsuaki.;Hirotoshi Watanabe.;Takeshi Morimoto.;Ko Yamamoto.;Yuki Obayashi.;Ryusuke Nishikawa.;Kenji Ando.;Satoru Suwa.;Tsuyoshi Isawa.;Hiroyuki Takenaka.;Ruka Yoshida.;Hiroshi Suzuki.;Gaku Nakazawa.;Takanori Kusuyama.;Itsuro Morishima.;Syun Hojo.;Joshi Tsutsumi.;Hirosada Yamamoto.;Hiroshi Ueda.;Koh Ono.;Takeshi Kimura.
来源: Circ Cardiovasc Interv. 2025年18卷7期e015197页
The effects of the aspirin-free strategy on bleeding and cardiovascular events were unknown in patients with high bleeding risk (HBR), with or without acute coronary syndrome (ACS), undergoing percutaneous coronary intervention.
18. Impact of Natriuretic Peptide and Prior Hospitalization in Patients With Severe Mitral Regurgitation: COAPT Trial.
作者: Sachin S Goel.;Ashrith Guha.;JoAnn Lindenfeld.;William T Abraham.;Saibal Kar.;Samir R Kapadia.;Stephen H Little.;D Scott Lim.;Michael J Reardon.;Neal S Kleiman.;Janani Aiyer.;Lak N Kotinkaduwa.;Michael J Mack.;Gregg W Stone.
来源: Circ Cardiovasc Interv. 2025年18卷7期e015192页
The clinical significance of elevated baseline natriuretic peptide level and prior heart failure hospitalization (HFH) within the prior year in mitral transcatheter edge-to-edge repair outcomes is unclear. This analysis examined the impact of BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal pro-B-type natriuretic peptide) and prior HFH on outcomes in patients with severe secondary mitral regurgitation.
19. Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.
作者: Constantin-Cristian Topriceanu.;Christoffer Rasmus Vissing.;Anna Axelsson Raja.;Sharlene M Day.;Mark W Russell.;Kenneth Zahka.;Alexandre C Pereira.;Steven D Colan.;Anne M Murphy.;Charles Canter.;Richard G Bach.;Matthew T Wheeler.;Joseph W Rossano.;Anjali T Owens.;Luisa Mestroni.;Matthew R G Taylor.;James C Moon.;Gabriella Captur.;Amit R Patel.;Ivan Wilmot.;Jonathan H Soslow.;Jason R Becker.;Christine E Seidman.;Neal K Lakdawala.;Henning Bundgaard.;Usman A Tahir.;Carolyn Y Ho.
来源: Circ Heart Fail. 2025年18卷6期e012393页
In hypertrophic cardiomyopathy (HCM), the mechanisms through which pathogenic sarcomere variants (G+) lead to left ventricular hypertrophy (LVH) are not understood.
20. Novel Contrast-Derived Indices of Coronary Microvascular Function: Potential Clinical and Cost Benefits.
作者: Daniel T Y Ang.;Damien G Collison.;Ross J McGeoch.;David Carrick.;Robert A Sykes.;Conor Bradley.;Anna L Kamdar.;Andy Jong.;Richard A Brogan.;David A MacDougall.;Peter J McCartney.;J Paul Rocchiccioli.;Andrew P Apps.;C Aengus Murphy.;Keith E Robertson.;Aadil Shaukat.;Angie Ghattas.;Francis R Joshi.;Arvind Sood.;Richard I S Good.;Brian O'Rourke.;Hany Eteiba.;M Mitchell Lindsay.;Alex McConnachie.;Colin Berry.
来源: Circ Cardiovasc Interv. 2025年18卷6期e015058页
Intravenous adenosine induces stable myocardial hyperemia for coronary microvascular function testing. Iodinated radiographic contrast media induce transient, submaximal hyperemia. We assessed the feasibility, diagnostic value, and potential cost-effectiveness of contrast-derived indices of microvascular function.
|